US 12,227,576 B2
Methods of treating a tumor using an anti-PD-1 antibody
Robin Edwards, Newtown, PA (US); William J. Geese, Pipersville, PA (US); and Danielle M. Greenawalt, Philadelphia, PA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Jan. 30, 2023, as Appl. No. 18/161,713.
Application 18/161,713 is a continuation of application No. 16/617,725, granted, now 11,566,073, previously published as PCT/US2018/035670, filed on Jun. 1, 2018.
Claims priority of provisional application 62/513,831, filed on Jun. 1, 2017.
Prior Publication US 2023/0279114 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01)] 20 Claims
 
1. A method of treating a subject afflicted with a tumor derived from a lung cancer comprising, (i) determining a mutation status of an STK11 gene in the subject; and (ii) administering to the subject an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (“anti-PD-1 antibody”), wherein the subject is identified as having (i)_a wild-type STK11 gene and (ii) a mutated marker gene comprising PTPRD, CUBN, or a combination thereof; and wherein the tumor exhibits a diffuse membranous PD-L1 expression.